Mark A. Emalfarb Sells 44,000 Shares of Dyadic International, Inc. (NASDAQ:DYAI) Stock

Dyadic International, Inc. (NASDAQ:DYAI) CEO Mark A. Emalfarb sold 44,000 shares of the firm’s stock in a transaction on Monday, June 7th. The stock was sold at an average price of $3.95, for a total transaction of $173,800.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of NASDAQ DYAI opened at $3.74 on Friday. The business has a fifty day moving average of $4.36. The firm has a market cap of $103.05 million and a price-to-earnings ratio of -11.00. Dyadic International, Inc. has a 1-year low of $3.34 and a 1-year high of $10.98.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Monday, March 29th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Dyadic International had a negative return on equity of 35.81% and a negative net margin of 595.37%. On average, research analysts anticipate that Dyadic International, Inc. will post -0.4 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Axiom Investment Management LLC bought a new position in shares of Dyadic International during the 1st quarter worth approximately $366,000. Barclays PLC boosted its holdings in Dyadic International by 71.9% during the first quarter. Barclays PLC now owns 23,669 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 9,896 shares during the last quarter. Renaissance Technologies LLC grew its position in Dyadic International by 40.5% in the first quarter. Renaissance Technologies LLC now owns 38,400 shares of the biotechnology company’s stock valued at $211,000 after purchasing an additional 11,072 shares in the last quarter. Forefront Analytics LLC grew its position in Dyadic International by 24.7% in the first quarter. Forefront Analytics LLC now owns 29,210 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 5,794 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Dyadic International by 8.9% in the 1st quarter. Geode Capital Management LLC now owns 330,200 shares of the biotechnology company’s stock valued at $1,812,000 after buying an additional 27,008 shares during the last quarter. Hedge funds and other institutional investors own 19.71% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.

Featured Article: What is a dividend reinvestment plan?

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.